CN103619838A - 作为s1p1受体激动剂的新的哌啶基单羧酸 - Google Patents
作为s1p1受体激动剂的新的哌啶基单羧酸 Download PDFInfo
- Publication number
- CN103619838A CN103619838A CN201280022925.5A CN201280022925A CN103619838A CN 103619838 A CN103619838 A CN 103619838A CN 201280022925 A CN201280022925 A CN 201280022925A CN 103619838 A CN103619838 A CN 103619838A
- Authority
- CN
- China
- Prior art keywords
- benzyl
- diazole
- carboxylic acid
- chloro
- piperidines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **C(*)(CC1)CCN1C(*)c(cc1)ccc1-c1n[o]c([Al])n1 Chemical compound **C(*)(CC1)CCN1C(*)c(cc1)ccc1-c1n[o]c([Al])n1 0.000 description 2
- BPGRMXNUHVYMRV-UHFFFAOYSA-N CC(C)CC(CC1)(CCN1C(OC(C)(C)C)=O)C(O)=O Chemical compound CC(C)CC(CC1)(CCN1C(OC(C)(C)C)=O)C(O)=O BPGRMXNUHVYMRV-UHFFFAOYSA-N 0.000 description 2
- PDEXPGXVJVCMCM-UHFFFAOYSA-N C=[O]C(c1ccc(-c2ccccc2)c(N)c1)=O Chemical compound C=[O]C(c1ccc(-c2ccccc2)c(N)c1)=O PDEXPGXVJVCMCM-UHFFFAOYSA-N 0.000 description 1
- RJKFXHZAWNRVDC-UHFFFAOYSA-N CC(C)CC1(CCNCC1)C(O)=O Chemical compound CC(C)CC1(CCNCC1)C(O)=O RJKFXHZAWNRVDC-UHFFFAOYSA-N 0.000 description 1
- IBECIOUXTGNFPQ-UHFFFAOYSA-N CC(C)Cc(c(Cl)c1)ccc1-c1nc(-c2ccc(C(CC(C)(C)N)N(CC3)CCC3(CCOc(cccc3)c3OC)C(O)=O)cc2)n[o]1 Chemical compound CC(C)Cc(c(Cl)c1)ccc1-c1nc(-c2ccc(C(CC(C)(C)N)N(CC3)CCC3(CCOc(cccc3)c3OC)C(O)=O)cc2)n[o]1 IBECIOUXTGNFPQ-UHFFFAOYSA-N 0.000 description 1
- KDKJMZBICNRQQU-UHFFFAOYSA-N CC(C)Cc(c(Cl)c1)ccc1C(O)=O Chemical compound CC(C)Cc(c(Cl)c1)ccc1C(O)=O KDKJMZBICNRQQU-UHFFFAOYSA-N 0.000 description 1
- SLHMRNVMHALVQX-UHFFFAOYSA-N CCCCC(CC)(Cc1cccc(C)c1)C(O)=O Chemical compound CCCCC(CC)(Cc1cccc(C)c1)C(O)=O SLHMRNVMHALVQX-UHFFFAOYSA-N 0.000 description 1
- REEYDMXUOJQMIK-UHFFFAOYSA-N CCOC(C(CC(C)C)(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CCOC(C(CC(C)C)(CC1)CCN1C(OC(C)(C)C)=O)=O REEYDMXUOJQMIK-UHFFFAOYSA-N 0.000 description 1
- MYHJCTUTPIKNAT-UHFFFAOYSA-N CCOC(C(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CCOC(C(CC1)CCN1C(OC(C)(C)C)=O)=O MYHJCTUTPIKNAT-UHFFFAOYSA-N 0.000 description 1
- QYSNLVVLEBLLIV-UHFFFAOYSA-N CCOC(C(CCCN1CCCCC1)(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CCOC(C(CCCN1CCCCC1)(CC1)CCN1C(OC(C)(C)C)=O)=O QYSNLVVLEBLLIV-UHFFFAOYSA-N 0.000 description 1
- XDTRASKAQSEFQM-UHFFFAOYSA-N CCOC(C(COCc1ccccc1)(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CCOC(C(COCc1ccccc1)(CC1)CCN1C(OC(C)(C)C)=O)=O XDTRASKAQSEFQM-UHFFFAOYSA-N 0.000 description 1
- UEUPPZDCYXYTRK-UHFFFAOYSA-N CCOC(C1(CCOc2ccccc2)CCNCC1)=O Chemical compound CCOC(C1(CCOc2ccccc2)CCNCC1)=O UEUPPZDCYXYTRK-UHFFFAOYSA-N 0.000 description 1
- VGTBSHLLKRMGJX-UHFFFAOYSA-N CCOC(C1(Cc(cc2)ccc2OC)CCNCC1)=O Chemical compound CCOC(C1(Cc(cc2)ccc2OC)CCNCC1)=O VGTBSHLLKRMGJX-UHFFFAOYSA-N 0.000 description 1
- MPXCQVAYJKVGCJ-UHFFFAOYSA-N [NH-]C(C(c1ccccc1)=CC1)=CC1C(F)(F)F Chemical compound [NH-]C(C(c1ccccc1)=CC1)=CC1C(F)(F)F MPXCQVAYJKVGCJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305433.2 | 2011-04-12 | ||
EP11305433A EP2511275A1 (en) | 2011-04-12 | 2011-04-12 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
PCT/EP2012/056470 WO2012140020A1 (en) | 2011-04-12 | 2012-04-10 | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103619838A true CN103619838A (zh) | 2014-03-05 |
CN103619838B CN103619838B (zh) | 2016-08-24 |
Family
ID=43984071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280022925.5A Active CN103619838B (zh) | 2011-04-12 | 2012-04-10 | 作为s1p1受体激动剂的哌啶基单羧酸 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9266867B2 (zh) |
EP (2) | EP2511275A1 (zh) |
JP (1) | JP6050315B2 (zh) |
KR (1) | KR101854152B1 (zh) |
CN (1) | CN103619838B (zh) |
AU (1) | AU2012241981B2 (zh) |
BR (1) | BR112013026434B1 (zh) |
CA (1) | CA2833180C (zh) |
CO (1) | CO6801772A2 (zh) |
DK (1) | DK2697219T3 (zh) |
EA (1) | EA023638B1 (zh) |
EC (1) | ECSP13012983A (zh) |
ES (1) | ES2544616T3 (zh) |
HU (1) | HUE025443T2 (zh) |
IL (1) | IL228844A (zh) |
MA (1) | MA35305B1 (zh) |
MX (1) | MX342926B (zh) |
PL (1) | PL2697219T3 (zh) |
PT (1) | PT2697219E (zh) |
SG (1) | SG194183A1 (zh) |
TN (1) | TN2013000425A1 (zh) |
UA (1) | UA110822C2 (zh) |
WO (1) | WO2012140020A1 (zh) |
ZA (1) | ZA201307820B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332435A (zh) * | 2021-06-18 | 2021-09-03 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
CN111807954B (zh) * | 2019-04-10 | 2024-04-05 | 广东东阳光药业股份有限公司 | 一种辛波莫德中间体的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA123330C2 (uk) * | 2016-07-13 | 2021-03-17 | Лео Фарма А/С | Гетероароматичні модулятори ретинол-зв'язаного орфанного рецептора гамма |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105771A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
WO2009080730A1 (en) * | 2007-12-21 | 2009-07-02 | Glaxo Group Limited | 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases |
CN101784535A (zh) * | 2007-06-15 | 2010-07-21 | 生物计划公司 | 作为s1p1受体激动剂的新的二羧酸衍生物 |
CN101970420A (zh) * | 2007-10-04 | 2011-02-09 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7479504B2 (en) * | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
WO2007132307A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AU2007334436A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
BRPI0922135B1 (pt) * | 2008-12-05 | 2021-07-13 | Astellas Pharma Inc | Composto de 2h-cromeno ou um sal do mesmo, composição farmacêutica compreendendo dito composto e uso do mesmo para prevenir ou tratar uma doença induzida por infiltração de linfócito indesejável associada com s1p1 |
EP2305660A1 (en) * | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
EP2366702A1 (en) * | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
BR112013019683B1 (pt) * | 2011-02-07 | 2022-04-19 | Biogen Inc | Compostos que modulam s1p, composição farmacêutica, e uso dos mesmos |
-
2011
- 2011-04-12 EP EP11305433A patent/EP2511275A1/en not_active Withdrawn
-
2012
- 2012-04-10 SG SG2013076591A patent/SG194183A1/en unknown
- 2012-04-10 US US14/111,438 patent/US9266867B2/en active Active
- 2012-04-10 JP JP2014504282A patent/JP6050315B2/ja active Active
- 2012-04-10 CA CA2833180A patent/CA2833180C/en active Active
- 2012-04-10 WO PCT/EP2012/056470 patent/WO2012140020A1/en active Application Filing
- 2012-04-10 AU AU2012241981A patent/AU2012241981B2/en active Active
- 2012-04-10 HU HUE12714674A patent/HUE025443T2/en unknown
- 2012-04-10 EP EP12714674.4A patent/EP2697219B1/en active Active
- 2012-04-10 ES ES12714674.4T patent/ES2544616T3/es active Active
- 2012-04-10 CN CN201280022925.5A patent/CN103619838B/zh active Active
- 2012-04-10 PL PL12714674T patent/PL2697219T3/pl unknown
- 2012-04-10 PT PT127146744T patent/PT2697219E/pt unknown
- 2012-04-10 EA EA201301150A patent/EA023638B1/ru not_active IP Right Cessation
- 2012-04-10 MX MX2013011984A patent/MX342926B/es active IP Right Grant
- 2012-04-10 DK DK12714674.4T patent/DK2697219T3/en active
- 2012-04-10 BR BR112013026434-9A patent/BR112013026434B1/pt active IP Right Grant
- 2012-04-10 KR KR1020137030008A patent/KR101854152B1/ko active IP Right Grant
- 2012-10-04 UA UAA201313012A patent/UA110822C2/uk unknown
-
2013
- 2013-10-13 IL IL228844A patent/IL228844A/en active IP Right Grant
- 2013-10-14 TN TNP2013000425A patent/TN2013000425A1/fr unknown
- 2013-10-21 ZA ZA2013/07820A patent/ZA201307820B/en unknown
- 2013-10-21 EC ECSP13012983 patent/ECSP13012983A/es unknown
- 2013-10-22 MA MA36356A patent/MA35305B1/fr unknown
- 2013-11-12 CO CO13265458A patent/CO6801772A2/es not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105771A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
CN101784535A (zh) * | 2007-06-15 | 2010-07-21 | 生物计划公司 | 作为s1p1受体激动剂的新的二羧酸衍生物 |
CN101970420A (zh) * | 2007-10-04 | 2011-02-09 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
WO2009080730A1 (en) * | 2007-12-21 | 2009-07-02 | Glaxo Group Limited | 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111807954B (zh) * | 2019-04-10 | 2024-04-05 | 广东东阳光药业股份有限公司 | 一种辛波莫德中间体的制备方法 |
CN113332435A (zh) * | 2021-06-18 | 2021-09-03 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7199142B2 (en) | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | |
TWI804870B (zh) | 用以合成甲狀腺激素類似物及其多形體之方法 | |
TW200410946A (en) | Compounds | |
CN103596431A (zh) | 嘧啶环己基糖皮质激素受体调节剂 | |
CZ295346B6 (cs) | Pyrimidinové sloučeniny, způsob jejich přípravy, farmaceutická kompozice a jejich použití pro léčbu poruch souvisejících s ligandy dopaminu D3 | |
TW201215605A (en) | Manufacturing process for pyrimidine derivatives | |
EP2687531B1 (en) | Tetrahydrocarboline derivative | |
CN103619838A (zh) | 作为s1p1受体激动剂的新的哌啶基单羧酸 | |
CN108271370A (zh) | 作为p2y14受体拮抗剂的三唑衍生物 | |
CN103534250B (zh) | 用于治疗免疫障碍的被取代的吲哚衍生物 | |
WO2022114164A1 (ja) | ヘテロアリールカルボキシアミド化合物 | |
CN1234799A (zh) | 1,4-二取代的哌嗪 | |
CN101932574B (zh) | 用于治疗对多巴胺d3受体调节产生反应的病症的1,2,4-三嗪-3,5-二酮化合物 | |
CN103619831B (zh) | 唑类杂环化合物、其制备方法、药物组合物和用途 | |
TW201305130A (zh) | 突變雄激素受體拮抗藥 | |
MX2015001014A (es) | Antagonistas / agonistas inversos del receptor canabinoide. | |
US20030212110A1 (en) | Calcilytic compounds | |
AU2001276923A1 (en) | Calcilytic compounds | |
EP1368318A2 (en) | Calcilytic compounds | |
WO2021033729A1 (ja) | S1p5受容体作動活性を有する化合物の塩および結晶形 | |
US20100035924A1 (en) | Novel 4-amino-pyridine derivatives and their use as potassium channel modulators | |
EP3447045B9 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
JP2001515070A (ja) | 2−{3−[4−(2−t−ブチル−6−トリフルオロメチルピリジン−4−イル)ピペラジン−1−イル]プロピルメルカプト}ピリミジン−4−オル−フマレート | |
JP2021522265A (ja) | c−MET阻害剤の結晶形、及びその塩形、並びに調製方法 | |
WO2024059216A2 (en) | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194735 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1194735 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220114 Address after: Mumbai Patentee after: SUN PHARMA ADVANCED RESEARCH CO.,LTD. Address before: Paris France Patentee before: BIOPROJET Patentee before: Sun pharmaceutical Advanced Research Co., Ltd |
|
TR01 | Transfer of patent right |